Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Metastatic Breast Cancer at the ESMO Congress 2026. #ESMO26 $CELC #BCAM https://www.globenewswire.com/news-release/2026/10/24/3387663/0/en/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-study-in-patients-with-hr-her2-advanced-breast-cancer-at-the-esmo-congress-2026.html